MedPath

Statens Serum Institut

🇩🇰Denmark
Ownership
-
Established
1902-01-01
Employees
-
Market Cap
-
Website
https://www.ssi.dk/

Clinical Trials

40

Active:8
Completed:30

Trial Phases

5 Phases

Phase 1:15
Phase 2:5
Phase 3:7
+2 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (30 trials with phase data)• Click on a phase to view related trials

Phase 1
15 (50.0%)
Phase 3
7 (23.3%)
Phase 2
5 (16.7%)
Phase 4
2 (6.7%)
Not Applicable
1 (3.3%)

First-in-Human Trial of the Novel Tuberculosis Vaccine Candidate, H107e/CAF®10b

Phase 1
Recruiting
Conditions
Healthy
Interventions
Biological: H107e/CAF®10b - full adjuvant dose
Biological: H107e
Biological: CAF®10b
Biological: H107e/CAF®10b
Biological: H107e/CAF®10b - low adjuvant dose
Biological: i.m. placebo
Biological: Full dose intranasal H107e
Biological: Low dose intranasal H107e
Biological: i.d. placebo
Biological: Intranasal H107e
First Posted Date
2023-09-22
Last Posted Date
2025-05-13
Lead Sponsor
Statens Serum Institut
Target Recruit Count
140
Registration Number
NCT06050356
Locations
🇿🇦

Aurum Institute, Pretoria, Gauteng, South Africa

Safety and Immunogenicity of a Chlamydia Vaccine CTH522

Phase 1
Completed
Conditions
Trachoma
First Posted Date
2019-04-24
Last Posted Date
2024-08-22
Lead Sponsor
Statens Serum Institut
Target Recruit Count
65
Registration Number
NCT03926728
Locations
🇬🇧

NIHR Imperial Center for Translational and Experimental Medicine, London, United Kingdom

Immunogenicity and Safety of Adjuvanted Reduced Dose Inactivated Polio Vaccine Given as a Booster at Age 15-18 Months

Phase 3
Completed
Conditions
Poliomyelitis
First Posted Date
2018-09-14
Last Posted Date
2018-11-14
Lead Sponsor
Statens Serum Institut
Target Recruit Count
666
Registration Number
NCT03671616
Locations
🇵🇦

Cevaxin, Panama City, Panama

Safety and Immunogenicity of Adjuvanted Reduced Dose Inactivated Polio Vaccine Given at 6, 10, 14 Weeks and 9 Months

Phase 3
Completed
Conditions
Poliomyelitis
First Posted Date
2017-01-26
Last Posted Date
2018-11-14
Lead Sponsor
Statens Serum Institut
Target Recruit Count
1002
Registration Number
NCT03032419
Locations
🇵🇭

5 sites in Philippines, Manila, Philippines

Safety and Immunogenicity of Adjuvanted Reduced Dose Inactivated Polio Vaccine in 2, 4, 6 Months of Age

Phase 3
Completed
Conditions
Poliomyelitis
First Posted Date
2017-01-19
Last Posted Date
2018-11-14
Lead Sponsor
Statens Serum Institut
Target Recruit Count
800
Registration Number
NCT03025750
Locations
🇵🇦

Cevaxin, Panama City, Panama

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.